The Sputnik V coronavirus vaccine, based on the same platform used to develop the Ebola drug, is likely to protect the body for two years, [TASS] reports (https://tass.ru/obschestvo/10242481) with reference to the head of the Gamaleya Research Center for Epidemiology and Microbiology of the Russian Ministry of Health, Alexander Gintsburg, who developed the vaccine. “I can only assume now that experimental data are needed. As far as our vaccine is concerned, the platform from which it was created, the Ebola vaccine was created on it. There is experimental data showing that this similar vaccine preparation gives protection for at least two years, maybe more, - he said on the air of the YouTube channel Soloviev Live. Gunzburg also added that the Sputnik V vaccine guarantees its effectiveness in 96% of cases. Only in 4% of cases, a vaccinated person can still get sick, but the disease will pass in a mild form in the form of a runny nose, cough, or with a low temperature, while the pathogen will not sink into the lungs. On December 11, the US Food and Drug Administration (FDA) approved an application by BioNTech and Pfizer to register their vaccine under an accelerated emergency procedure.